April 21 (Reuters) - Dublin-based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company.
Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros ($2.66 billion) acquisition of Omega Pharma and new products that are expected to generate about $1 billion in revenue.
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High5
21:52 Netflix nears 94 million subscribers 10 years after streaming launch18
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft14
12:23 Morgan Stanley beats, has a record-breaking quarter for wealth management18